Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

被引:30
作者
McCaughan, Georgia J. B. [3 ]
Fulham, Michael J. [1 ,3 ]
Mahar, Annabelle [3 ]
Soper, Judy [3 ,4 ]
Hong, Angela M. [1 ,2 ]
Stalley, Paul D. [3 ]
Tattersall, Martin H. N. [1 ,2 ]
Bhadri, Vivek A. [1 ,2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[2] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia
[4] Specialist Magnet Resonance Imaging, Newton, NSW, Australia
来源
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2016年 / 9卷
关键词
Ewing sarcoma; Immunotherapy; Anti-programmed cell death-1 antibody; Case report; GENOMIC INSTABILITY; CANCER; SURVIVAL; EXPERIENCE; NIVOLUMAB; ANTIBODY; THERAPY; REPAIR; FAMILY; TUMORS;
D O I
10.1186/s13045-016-0278-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Zanella, Anais
    Doussot, Alexandre
    Puzenat, Eve
    Aubin, Francois
    Nardin, Charlee
    MELANOMA RESEARCH, 2020, 30 (06) : 606 - 607
  • [32] Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent
    van Erp, Anke E. M.
    Versleijen-Jonkers, Yvonne M. H.
    Hillebrandt-Roeffen, Melissa H. S.
    van Houdt, Laurens
    Gorris, Mark A. J.
    van Dam, Laura S.
    Mentzel, Thomas
    Weidema, Marije E.
    Savci-Heijink, C. Dilara
    Desar, Ingrid M. E.
    Merks, Hans H. M.
    van Noesel, Max M.
    Shipley, Janet
    van der Graaf, Winette T. A.
    Flucke, Uta E.
    Meyer-Wentrup, Friederike A. G.
    ONCOTARGET, 2017, 8 (41) : 71371 - 71384
  • [33] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441
  • [34] Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer
    Remon, Jordi
    Chaput, Nathalie
    Planchard, David
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) : 122 - 129
  • [35] Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
    Evans, Vanessa A.
    van der Sluis, Renee M.
    Solomon, Ajantha
    Dantanarayana, Ashanti
    McNeil, Catriona
    Garsia, Roger
    Palmer, Sarah
    Fromentin, Remi
    Chomont, Nicolas
    Sekaly, Rafick-Pierre
    Cameron, Paul U.
    Lewin, Sharon R.
    AIDS, 2018, 32 (11) : 1491 - 1497
  • [36] Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors
    Omori, R.
    Eguchi, J.
    Hiroishi, K.
    Ishii, S.
    Hiraide, A.
    Sakaki, M.
    Doi, H.
    Kajiwara, A.
    Ito, T.
    Kogo, M.
    Imawari, M.
    CANCER GENE THERAPY, 2012, 19 (09) : 637 - 643
  • [37] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [38] Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors
    R Omori
    J Eguchi
    K Hiroishi
    S Ishii
    A Hiraide
    M Sakaki
    H Doi
    A Kajiwara
    T Ito
    M Kogo
    M Imawari
    Cancer Gene Therapy, 2012, 19 : 637 - 643
  • [39] Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
    Zhu, Xinxin
    Lang, Jinghe
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (05)
  • [40] The path forward for anti-programmed cell death-1 therapy in gliomas
    Majd, Nazanin
    Kamiya-Matsuoka, Carlos
    de Groot, John
    CURRENT OPINION IN NEUROLOGY, 2019, 32 (06) : 864 - 871